Stopping GLP-1s for Pregnancy Linked to Weight Gain, ComplicationsStopping GLP-1s for Pregnancy Linked to Weight Gain, Complications
(MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and higher risks of pregnancy complications, according to an analysis of health records that primarily… (MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and Read More
How to Make Treatment Decisions in Breast Cancer Without Genomic AssaysHow to Make Treatment Decisions in Breast Cancer Without Genomic Assays
(MedPage Today) — In resource-limited settings, genomic assays for hormone receptor-positive, HER2-negative breast cancer aren’t always accessible. Yet treatment decisions still need to be made — often quickly and with limited information…
People who stop using Mounjaro tend to regain weight and lose other health benefits, says studyPeople who stop using Mounjaro tend to regain weight and lose other health benefits, says study
Improvements such as reduced ‘bad’ cholesterol and lower blood pressure go into reverse upon stopping weight-loss jabs People who stop using the weight-loss jab Mounjaro not only tend to regain weight, but experience a reversal in other health improvements too, research suggests. Mounjaro, which contains the active ingredient tirzepatide, has become a popular medication for Read More
STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaksSTAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more. Can a GLP-1 drug slow Alzheimer’s Read More
STAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progressionSTAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression
Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the progression of the condition versus placebo. Studying semaglutide — the key ingredient in the blockbusters Ozempic and Wegovy — in Alzheimer’s was always seen as a long shot, even as Read More
Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event riskDulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with type 2 diabetes (T2DM). 2. All three agents were associated with an increased risk of gastrointestinal AEs, particularly motility-related events, compared with sodium-glucose cotransporter-2 inhibitors (SGLT-2is). Evidence Rating Level: 2 (Good) Study Rundown: GLP-1 receptor Read More
Daily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial findsDaily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial finds
A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher. A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose Read More
Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s whyMaking GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s why
The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars. The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement Read More
New evidence shows tirzepatide and semaglutide strongly protect the heartNew evidence shows tirzepatide and semaglutide strongly protect the heart
A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs. A massive real-world study comparing tirzepatide and Read More
Why some people are microdosing GLP-1Why some people are microdosing GLP-1
NBC News’ Anne Thompson joins “Here’s the Scoop” co-host Yasmin Vossoughian to talk about why some people are microdosing GLP-1 medications. NBC News’ Anne Thompson joins “Here’s the Scoop” co-host Yasmin Vossoughian to talk about why some people are microdosing GLP-1 medications.